Business

Associated Press
FILE – In this March 13, 2012 file photo, Natco Pharma Ltd. Secretary and General Manager Legal and Corp. Affairs M. Adinarayana displays Sorafenib Tosylate drugs meant for cancer treatment, at the company’s head office in Hyderabad, India. India's patent appeals office on Monday, March 4, 2013, rejected international drug maker Bayer AG's plea to stop Indian company Natco Pharma Ltd. from manufacturing a cheaper generic version of a patented cancer drug. Bayer Corp., a subsidiary of the German pharma giant in Pittsburgh, Pennsylvania, markets sorefinib as Nexavar for about $5,600. Natco's version would cost Indian patients $175 a month. (AP Photo/Mahesh Kumar A., File)

View gallery

500 photos

Economy, business and finance photos

View Comments